<DOC>
	<DOCNO>NCT00003897</DOCNO>
	<brief_summary>RATIONALE : Vaccines make gp100 sargramostim may make body build immune response kill tumor cell . PURPOSE : Phase I trial study effectiveness vaccine therapy gp100 and/or sargramostim treat patient malignant melanoma .</brief_summary>
	<brief_title>Vaccine Therapy With gp100 and/or Sargramostim Treating Patients With Malignant Melanoma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine safety toxicity vivo particle bombardment DNA coat gold bead carry cDNA gp100 , without gold bead carry cDNA sargramostim ( GM-CSF ) , uninvolved skin patient melanoma . II . Estimate intensity duration gp100 transgene expression follow regimens patient . III . Assess local lymphocyte phenotype systemic lymphocyte function follow regimens patient . IV . Compare gp100 transgene expression well local lymphocyte phenotype systemic lymphocyte function cDNA GM-CSF administer 3 day cDNA gp100 vs day gp100 administration patient . V. Determine effect regimens tumor shrinkage , histological evidence tumor inflammation necrosis , vitro evidence antitumor immune reactivity patient . OUTLINE : This dose escalation study . Patients assign one three treatment group . Group I : Patients receive particle mediate gene transfer ( PMGT ) gp100 day 1 2 4 separate site . One site biopsied day 3 . A second course administer day 22 one site biopsied day 26 . Delayed type hypersensitivity ( DTH ) assess day 40 43 . Group II : Patients receive PMGT sargramostim ( GM-CSF ) day 1 1-5 separate site . PMGT gp100 administer 2-4 site day 4 . One gp100 site biopsied day 6 . A second course administer begin day 22 , one site biopsied day 29 . DTH assess day 40 43 . Group III : Patients receive PMGT GM-CSF combination gp100 day 1 2 4 separate site . Courses administer group I . Patients achieve partial complete response maintain stable disease may receive another course therapy . Cohorts 3-6 patient treat dose group maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose limit toxicity . Patients follow 3 , 6 , 12 month , annually thereafter . PROJECTED ACCRUAL : A total 18 patient accrue study .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically prove malignant melanoma surgically medically incurable Measurable evaluable metastatic disease OR No evidence disease follow surgical resection distant metastasis OR Surgical resection least 2 local regional recurrence , least 1 evidence lymph node involvement Each recurrence least 1 month apart PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 0 1 Life expectancy : Greater 3 month Hematopoietic : WBC least 3500/mm3 Platelet count least 100,000/mm3 Hemoglobin least 10.0 g/dL Hepatic : Bilirubin le 2.0 mg/dL SGOT le 3 time normal Renal : Creatinine le 2.0 mg/dL Other : Not pregnant Fertile patient must use effective contraception HIV negative No active infection require antibiotic , antiviral , antifungal therapy No active malignancy No concurrent significant illnesses PRIOR CONCURRENT THERAPY : Biologic therapy : At least 1 month since prior immunotherapy Chemotherapy : At least 1 month since prior chemotherapy No 2 prior chemotherapy regimens melanoma Endocrine therapy : At least 1 month since prior steroid ( except intermittent use antiemetic topical agent ) No concurrent steroid Radiotherapy : At least 1 month since prior radiotherapy No prior radiotherapy vaccine site Surgery : No prior organ allograft</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>stage IV melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
</DOC>